Abivax’s U.S.-listed ADSs were down 6.38% to $102.45 in the latest session, with the tape showing a pullback that traders tied to digestion of the company’s most recent corporate update rather than a fresh, same-day catalyst. The company released full-year 2025 financial results and program timing on March 23, 2026, highlighting its runway outlook and reiterating upcoming milestones for obefazimod in ulcerative colitis; the next major inflection remains the pivotal Phase 3 maintenance trial completion expected in late Q2 2026.

In the March 23, 2026 update, Abivax emphasized continued progress in its Phase 3 ABTECT-UC maintenance program and noted that a Data Safety Monitoring Board safety review completed on March 18, 2026 reported no new safety signals. The same update also framed the regulatory path as contingent on positive maintenance data, with an NDA submission target in Q4 2026 (subject to positive results), keeping the stock highly sensitive to any shifts in perceived probability of success and timeline confidence.

After prior large moves around clinical data and financing, ABVX has remained prone to sharp, sentiment-driven swings as the market trades the gap between “known” induction results and the still-pending maintenance dataset. With maintenance results not yet in hand and the next catalyst window approaching (late Q2 2026), even modest changes in risk appetite can prompt profit-taking, de-risking, and volatility—especially when investors rotate among high-beta biotech names ahead of binary trial events.